Frederick, MD – June 9, 2025: StageBio has announced plans to incorporate its capabilities and staff from its Jackson, VA location into its facility in Frederick, MD.

Going forward, the Frederick, MD facility will serve as the company’s flagship office and laboratory. According to StageBio President and CEO, David Bruning, the consolidation will bring the company’s best minds and technologies under one roof to strengthen collaboration and better serve the needs of StageBio clients.

“By bringing our teams together in one state-of-the-art location, we are positioning StageBio for continued growth and innovation," said David Bruning, President and CEO of StageBio. “We look forward to continuing to serve our clients worldwide.”

The move also allows StageBio to better seamlessly integrate its offerings across tissue analysis, efficacy determination, toxicological evaluation, and detailed reporting. The proximity of collaborators and technologies across disciplines and services will result in expedited services, faster communication, and a more streamlined experience for clients.

For more information regarding the preclinical and clinical capabilities services of StageBio, contact us at www.stagebio.com/contact. 

About StageBio

StageBio is a leading provider of GLP-compliant necropsy, histology, pathology and specimen archiving services for the biopharmaceutical, medical device, academic, government and contract research industries. The company operates two GLP laboratories and a  GLP specimen archiving facilities in the U.S. and Europe, with substantial continued investment in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 20+ board-certified veterinary pathologists and more than 100 laboratory personnel on staff supporting our unified commitment to quality, scientific integrity and client satisfaction. Learn more at  www.stagebio.com.